CD4 and rheumatoid arthritis: In addition to MTX therapy for RA, one patient with TFH+ PTCL (Case No. 3) and another with CD4+ large cell PTCL-NOS (Case No. 8) received TNF inhibitor (adalimumab) or anti-IL6 receptor antibody (Ab) (tocilizumab) and azathioprine.